A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is to examine the safety, tolerability, pharmacokinetics and functional activity
of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic
asthma.